TGA
Consumers and health professionals are advised that Phebra Pty Ltd, in consultation with the TGA, has initiated a product defect alert for bottles of Ospolot (sulthiame) 200 mg tablets.
The affected batch numbers are:
- 18003717 (expiry 05/21)
- 28811 (expiry 11/22)
Ospolot (sulthiame) 200 mg tablets are used as an anticonvulsant for behavioural disorders associated with epilepsy; hyperkinetic behaviour; temporal lobe epilepsy; myoclonic seizures; grand mal attacks and Jacksonian seizures.
It has been identified that affected batches of Ospolot (sulthiame) 200 mg tablets have been supplied with child-resistant caps that may not function correctly. If this occurs, a child may be able to open a bottle and access the medicine, which could result in a potentially life-threatening risk.
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
